Korio

San Francisco, United States Founded: 2021 • Age: 5 yrs
Software for clinical trial supply management and randomization is provided.

About Korio

Korio is a Healthcare company based in San Francisco (United States) founded in 2021 by Chuck Harris and Ryan Keane. Software for clinical trial supply management and randomization is provided. Korio has raised $12.3 million across 2 funding rounds from investors including BIP Ventures, Excelerate Health Ventures and Boston Millennia Partners. Its chief executive, as recorded, is Ryan Keane. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Clinical Trials. Its competitors include Endpoint Clinical, Mosiac InVivo and Clinapps.

Company details

Korio was founded in 2021 in San Francisco, United States, as a provider in the health technology sector. An IRT platform is offered by the company for clinical trial randomization, supply management, and design. Operations focus on supporting pharmaceutical and biotech firms with tools for efficient trial logistics. The domain korioclinical.com is used for its online presence. Co-founders include Chuck Harris and Ryan Keane, with Keane serving as CEO.

  • Headquarters San Francisco, United States
  • Founders Chuck Harris, Ryan Keane
  • Sectors
    Healthcare
  • Website korioclinical.com
  • Social LinkedIn
Key Metrics
  • Total Equity Funding
    $12.3M (USD)

    in 2 rounds

  • Latest Funding Round
    $5.5M (USD), Series A

    Aug 2024

  • Investors

Funding Insights of Korio

Korio has successfully raised a total of $12.3M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $5.5 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $12.3M
  • Total Rounds 2
  • Last Round Series A β€” $5.5M
  • First Round $6.8M

    (Oct 2023)

  • Investors Count 3

All 2 funding rounds of Korio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Aug 2024$5.5MSeries A–BIP Ventures
Oct 2023$6.8MSeed–Excelerate Health Ventures
Valuation history

3 investors in total: 3 institutional.

Investors in Korio

Korio has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include BIP Ventures, Excelerate Health Ventures and Boston Millennia Partners.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Venture capital investments are provided by BIP Ventures.
bipventures.vcAtlanta, United States
Venture capital is provided for AI-driven healthcare innovations.
exceleratehealth.com
US-focused private equity and venture capital investments are managed.
bostonmillenniapartners.comBoston, United States
Premium access

Investor details for Korio

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Korio

6 people are tracked at Korio (5 in leadership, 1 in team).

NameRoleGroup
Chuck Harris
Co-FounderLeadership
Ryan Keane
Co-Founder & CEOLeadership
Danielle Chmelewski
Director Of Business DevelopmentLeadership
Colin Phillips
Vice President Of EngineeringLeadership
Philip Letcavage
Senior Director Of Business DevelopmentLeadership
Patrick O'Brien
Software DeveloperTeam
Premium access

Complete people profiles for Korio

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Korio

3 dated milestones of Korio across 3 years, from founding to its latest funding, stage changes and deals.

  1. Founded Korio is founded.
  2. Funding First funding round of $6.8M.
  3. Funding Latest funding round, Series A, of $5.5M.

Competitors of Korio

Korio has 3 listed competitors in our database. They include Endpoint Clinical, Mosiac InVivo and Clinapps.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
endpointclinical.com2009San Francisco, United States
Interactive Response Technology systems are provided for clinical trials.
mosaicinvivo.net2010San Jose, United States
Software solutions for pre-clinical scientific data management in life sciences.
clinapps.com1999San Diego, United States
Software products and services for the pharmaceutical and biotechnology industries
Premium access

Detailed competitors of Korio

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Korio

The website of Korio (korioclinical.com) receives about 1.4K visits a month.

  • Monthly visits
    1.4K

    ▲ 31.5% vs previous month

Top companies in Life Sciences Platforms & Tools

3 companies that operate in the same segment as Korio (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Medidata is recognized as a leading provider of SaaS solutions for clinical research.
1999New York, New York, United StatesUSD 41.5 M
AI-based solutions for health management are provided.
2015Dallas, Texas, United StatesUSD 2.8 B1,111
Real-world health data is provided for research and decisions.
2012Menlo Park, California, United StatesUSD 259.16 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Korio

Premium access

Complete news archive for Korio

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Korio

Korio was founded in 2021 and raised its 1st funding round 2 years after it was founded.

Korio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Ryan Keane is the CEO of Korio, as recorded in our data. They have also founded this company.

Korio is a funded company, having raised a total of $12.3M across 2 funding rounds to date. The company's 1st funding round was a Seed of $6.8M, raised on Oct 2023.

Korio was founded in 2021 in San Francisco, United States, as a provider in the health technology sector. An IRT platform is offered by the company for clinical trial randomization, supply management, and design. Operations focus on supporting pharmaceutical and biotech firms with tools for efficient trial logistics. The domain korioclinical.com is used for its online presence. Co-founders include Chuck Harris and Ryan Keane, with Keane serving as CEO.

Korio's top competitors include Endpoint Clinical, Clinapps and Mosiac InVivo.

Korio has 3 investors. Key investors include BIP Ventures, Excelerate Health Ventures, and Boston Millennia Partners.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available